Improved antitumor efficacy of paclitaxel with nano-formulation in breast cancer
Source abstract
Abstract
Abstract Breast cancer has been brought to the forefront of scientific research because of its increasing incidence as well as the growing demands to prolong the life span of patients and improve their quality of life. Paclitaxel (PTX), a small-molecule cytotoxic agent, is one of the most effective anti-cancer drugs against a variety of solid tumors, including breast cancer. Taxol®, a commercial preparation of PTX, has been widely used for the treatment of breast cancer since its approval for use by the US Food and Drug Administration in 1994. However, further development is limited by its poor aqueous solubility and by P-gp substrate and complex synthesis caused by excipient (Cremophor EL) used. Thus, there exist an urgent need to design and develop new-generation formulations of PTX, especially nano-formulations, to maximize the therapeutic effects and minimize the side effects. This paper provides a comprehensive review of the treatment of breast cancer with different formulations of PTX.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Treatment and Pharmacology · Nanoparticle-Based Drug Delivery · HER2/EGFR in Cancer Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of China
References (100+)
Show source-provided references
1. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers10.1016/j.biomaterials.2009.11.077 ↗
2. nab-Paclitaxel dose and schedule in breast cancer10.1186/s13058-015-0587-y ↗
3. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer10.1007/s10549-007-9591-y ↗
4. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer10.1200/JCO.2005.04.937 ↗
5. Pharmacokinetics of paclitaxel-containing liposomes in rats
6. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response10.1016/j.jconrel.2014.10.010 ↗
7. Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model
8. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles10.1016/j.biomaterials.2011.07.032 ↗
9. D-alpha-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery
10. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo10.1016/j.biomaterials.2016.01.049 ↗
11. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel10.1016/j.biomaterials.2012.10.029 ↗
12. Neoadjuvant therapy for early-stage breast cancer: current practice, controversies, and future directions
13. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer10.1097/COC.0b013e31826e0550 ↗
14. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery10.1016/j.biomaterials.2011.01.038 ↗
15. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane(R)10.1016/j.colsurfb.2013.07.036 ↗
16. Abraxane(R) versus Taxol(R) for patients with advanced breast cancer: a prospective time and motion analysis from a Chinese health care perspective10.1177/1078155214556008 ↗
17. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy10.1200/JCO.2010.29.5865 ↗
18. A systematic overview of chemotherapy effects in breast cancer10.1080/02841860120784 ↗
19. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer10.1021/jm500766w ↗
20. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model10.1158/1535-7163.MCT-13-0132 ↗
21. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles10.1016/j.biomaterials.2008.10.062 ↗
22. Emerging nanotherapeutic strategies in breast cancer10.1016/j.breast.2013.10.006 ↗
23. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles10.1016/j.biomaterials.2008.10.062 ↗
24. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy10.1007/s11095-014-1512-2 ↗
25. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery10.1016/j.biomaterials.2011.01.038 ↗
26. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles10.1016/j.biomaterials.2011.07.032 ↗
27. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells10.1007/s11095-007-9425-y ↗
28. Abraxane(R) versus Taxol(R) for patients with advanced breast cancer: a prospective time and motion analysis from a Chinese health care perspective10.1177/1078155214556008 ↗
29. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo10.1021/mp500399j ↗
30. Recent advances in design, synthesis and bioactivity of paclitaxel-mimics10.1016/j.fitote.2016.02.010 ↗
31. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer10.1371/journal.pone.0024075 ↗
32. Pharmacokinetics of paclitaxel-containing liposomes in rats
33. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer10.1097/COC.0b013e31826e0550 ↗
34. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions
35. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer
36. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer10.1371/journal.pone.0024075 ↗
37. Treatment of HER2 positive advanced breast cancer with T-DM1: a review of the literature10.1016/j.critrevonc.2015.08.011 ↗
38. Neoadjuvant therapy for early-stage breast cancer: current practice, controversies, and future directions
39. Taxol–a new cytostatic drug for therapy of ovarian and breast cancer
40. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer10.1038/nmat1737 ↗
41. Recent advances in design, synthesis and bioactivity of paclitaxel-mimics10.1016/j.fitote.2016.02.010 ↗
42. Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation10.3109/10837450.2014.965323 ↗
43. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery10.1016/j.addr.2006.01.023 ↗
44. Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis10.1039/C4NR07450E ↗
45. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis10.1093/annonc/mdr300 ↗
46. PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers10.1016/j.biomaterials.2012.10.073 ↗
47. Paclitaxel formulations: challenges and novel delivery options10.2174/1567201811666140609154949 ↗
48. Development and in vivo evaluation of an oral drug delivery system for paclitaxel10.1016/j.biomaterials.2010.09.036 ↗
49. Cancer statistics, 201610.3322/caac.21332 ↗
50. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer10.1038/nmat1737 ↗
51. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer10.1021/jm500766w ↗
52. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model10.1016/j.msec.2015.04.012 ↗
53. Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model
54. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions
55. Cytotoxicity of liposomal Paclitaxel in breast cancer cell line mcf-710.1007/s12291-013-0296-1 ↗
56. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers10.1016/j.biomaterials.2009.11.077 ↗
57. Development and in vivo evaluation of an oral drug delivery system for paclitaxel10.1016/j.biomaterials.2010.09.036 ↗
58. Enhanced cytotoxicity to cancer cells by co-delivery and controlled release of paclitaxel-loaded sirolimus conjugated albumin nanoparticles10.1111/cbdd.12750 ↗
59. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
60. D-alpha-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery
61. Cytotoxicity of liposomal Paclitaxel in breast cancer cell line mcf-710.1007/s12291-013-0296-1 ↗
62. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery10.1016/j.addr.2006.01.023 ↗
63. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo10.1021/mp500399j ↗
64. Experimental design of a liposomal lipid system: a potential strategy for paclitaxel-based breast cancer treatment10.1016/j.colsurfb.2015.09.055 ↗
65. Cancer statistics, 201610.3322/caac.21332 ↗
66. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery
67. Treatment of HER2 positive advanced breast cancer with T-DM1: a review of the literature10.1016/j.critrevonc.2015.08.011 ↗
68. Enhanced cytotoxicity to cancer cells by co-delivery and controlled release of paclitaxel-loaded sirolimus conjugated albumin nanoparticles10.1111/cbdd.12750 ↗
69. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer10.1007/s10549-007-9591-y ↗
70. Paclitaxel formulations: challenges and novel delivery options10.2174/1567201811666140609154949 ↗
71. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model10.1158/1535-7163.MCT-13-0132 ↗
72. Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics10.1007/s11095-014-1506-0 ↗
73. Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy10.1016/j.biomaterials.2015.03.039 ↗
74. Taxol–a new cytostatic drug for therapy of ovarian and breast cancer
75. Cyclodextrin/paclitaxel complex in biodegradable capsules for breast cancer treatment10.1021/cm4019925 ↗
76. Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy10.1016/j.biomaterials.2015.03.039 ↗
77. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer10.1038/sj.bjc.6603332 ↗
78. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer10.1200/JCO.2005.04.937 ↗
79. Cyclodextrin/paclitaxel complex in biodegradable capsules for breast cancer treatment10.1021/cm4019925 ↗
80. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo10.1016/j.biomaterials.2016.01.049 ↗
81. Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics10.1007/s11095-014-1506-0 ↗
82. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model10.1016/j.msec.2015.04.012 ↗
83. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells10.1007/s11095-007-9425-y ↗
84. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel10.1016/j.biomaterials.2012.10.029 ↗
85. Co-loaded paclitaxel/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy10.1016/j.colsurfb.2016.01.032 ↗
86. Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation10.3109/10837450.2014.965323 ↗
87. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane(R)10.1016/j.colsurfb.2013.07.036 ↗
88. nab-Paclitaxel dose and schedule in breast cancer10.1186/s13058-015-0587-y ↗
89. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer10.1200/JCO.2009.26.2071 ↗
90. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer
91. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer10.1038/sj.bjc.6603332 ↗
92. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer10.1200/JCO.2009.26.2071 ↗
93. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer10.1200/JCO.2012.44.9694 ↗
94. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy10.1007/s11095-014-1512-2 ↗
95. Experimental design of a liposomal lipid system: a potential strategy for paclitaxel-based breast cancer treatment10.1016/j.colsurfb.2015.09.055 ↗
96. Co-loaded paclitaxel/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy10.1016/j.colsurfb.2016.01.032 ↗
97. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response10.1016/j.jconrel.2014.10.010 ↗
98. Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis10.1039/C4NR07450E ↗
99. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer10.1200/JCO.2012.44.9694 ↗
100. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery